{"metadata":{"topics":["Acceleration","Accountability","Accountant","Accounting","Accounting standard","Accuracy and precision","Ad valorem tax","Adjudication","Administrative law","Adverse effect","Americans with Disabilities Act of 1990","Applied ethics","Arbitration","Article Three of the United States Constitution","Article Two of the United States Constitution","Articles of incorporation","Artificial objects","Asset","Attention","Attorney's fee","Audit","Authentication","Balance sheet","Bankruptcy","Beneficial ownership","Board of directors","Broker","Building code","Bulletin board system","Business","Business economics","Business law","Business organizations","By-law","CE marking","Canada","Capacity (law)","Capital (economics)","Cash","Cause of action","Certificate of incorporation","Charter","China","Choice of law","Citizenship","Civil law (common law)","Civil law (legal system)","Cognition","Cognitive science","Collateral (finance)","Common law","Common stock","Communication","Companies","Company","Comparative law","Competition","Competition law","Computer","Computer program","Consent","Constitution","Constitutional law","Consultant","Consummation","Contract","Contract law","Copyright","Corporate action","Corporate capitalism","Corporate finance","Corporate governance","Corporate jargon","Corporate law","Corporate personhood","Corporate services","Corporation","Corporations","Cost","Court","Covenant (law)","Credit","Creditor","Creditors' rights","Culture","Currency","Custom","Damages","Dangerous goods","Data","Debt","Debt relief","Decree","Deed","Deed of trust (real estate)","Delaware","Delaware General Corporation Law","Diligence","Disability","Discovery (law)","Discretion","Dividend","Doctrines","Document","Documents","Domain name","Domicile (law)","Duty","Easement","Economic law","Economic sectors","Economics","Economy","Economy of the United States","Edict of Fontainebleau","Employee Retirement Income Security Act of 1974","Employee benefits","Employment","Encumbrance","Entity","Environmental law","Equity (finance)","Equity (law)","Equity securities","Ethical principles","Ethics","Event of default","Evidence","Exchange rate","Excise","Executive order","Executor","Existence","Expense","Factor income distribution","Failure","Fair dealing","Faith","Fax","Federal government of the United States","Federal judiciary of the United States","Fee","Fiduciary","Finance","Financial Industry Regulatory Authority","Financial accounting","Financial economics","Financial markets","Financial regulation","Financial reporting","Financial services","Financial statement","Financial statements","Financial transaction","Fiscal year","Force","Foreign exchange market","Form 10-K","Form 8-K","Forum selection clause","Franchising","Future","Generally Accepted Accounting Principles (United States)","Good faith","Goodwill (accounting)","Governance","Government","Government agencies","Government agency","Government finances","Government information","Government institutions","Government of the United States","Government-related organizations","Gross income","Guarantee","Health","Hong Kong","Human activities","Human communication","Income","Income tax in the United States","Indemnity","Indenture","Industries","Information","Injunction","Inspection","Insurance","Intellectual property","Intellectual property law","Intellectual works","Interest","Internal Revenue Code","International law","Internet","Interpersonal relationships","Invention","Investment","Investment Company Act of 1940","Investor","Jargon","Joint venture","Judgment (law)","Judicial discretion","Judiciaries","Judiciary","Jurisdiction","Jurisprudence","Justice","Know-how","Knowledge","Labour law","Land use","Landlord","Law","Law and economics","Law of agency","Law of obligations","Law of the United States","Lawsuit","Lawyer","Leadership","Lease","Ledger","Legal communication","Legal concepts","Legal doctrines and principles","Legal documents","Legal ethics","Legal fictions","Legal liability","Legal literature","Legal procedure","Legal remedy","Legal writing","Legislation","Liability (financial accounting)","License","Lien","Limited liability","Limited liability company","Limited partnership","Loan","Local ordinance","Love","Mail","Management","Market (economics)","Matter","Mechanics","Medication","Memorandum","Mergers and acquisitions","Metaphysics","Microeconomics","Minutes","Misconduct","Misrepresentation","Money","Monopoly (economics)","Morality","Mortgage law","Natural environment","Natural person","Natural resource","Natural resources law","Negligence","Negotiation","Net income","Net worth","Nevada","Nothing","OTC Bulletin Board","Occupational safety and health","Official documents","Omission (law)","Open government","Opinion","Option (finance)","Ordinary course of business","Organization","Ownership","Par value","Partnership","Patent","Patent application","Payment","Payments","Payroll","Pension","Percentage","Personal finance","Personality traits","Phantom stock","Philosophy","Phrase","Plant","Policy","Political economy","Political ideologies","Political science","Politics","Practice of law","Precedent","Preferred stock","Principles","Privacy","Private law","Professional ethics","Profit (accounting)","Property","Property law","Proprietary software","Prospectus (finance)","Proxy voting","Public administration","Public finance","Public law","Public policy","Public policy doctrine","Public records","Public sector","Public sphere","Question of law","Questionnaire","Real property","Reason","Reasonable person","Receipt","Recklessness (law)","Registered mail","Regulation","Regulatory compliance","Reimbursement","Republic","Request for information","Resource","Revenue","Rights","Risk","Roman law","Rules","SEC filing","Safety","Sarbanes–Oxley Act","Secretary of state","Section 28","Section summary of the Patriot Act, Title II","Securities (finance)","Securities Act of 1933","Securities Exchange Act of 1934","Securities regulation in the United States","Security (finance)","Security agreement","Security interest","Self-regulatory organization","Semiotics","Separation of powers","Service industries","Service mark","Service of process","Services (economics)","Severability","Share (finance)","Shareholder","Short (finance)","Signature","Social institutions","Social issues","Social policy","Sociological theories","Software","Sources","Special administrative regions of China","Specific performance","State Security Law in Bahrain","State court (United States)","Statute","Stock","Stock certificate","Stock market","Stock split","Stock transfer agent","Subject-matter jurisdiction","Subsidiary","Surety","Taiwan","Tax","Tax return (United States)","Technology","Telephone","Theories of law","Town","Trade","Trade name","Trade secret","Trademark","Treasury stock","Tribunal","Trust law","Truth","U.S. Securities and Exchange Commission","U.S. state","Unemployment","Unemployment benefits","Unenforceable","Unitary group","United States","United States business law","United States district court","United States dollar","United States economic policy","United States federal policy","United States law","United States person","United States securities law","Urban, rural, and regional economics","Value (ethics)","Value added","Vesting","Village","Virtue","Voting trust","Waiver","Warrant (finance)","Warranty","Windfall gain","Windfall profits tax","Withholding tax","Witness","Workers' compensation","Writ","Writing","Written communication","Xi'an","Yangling District","Zhao (state)","Zoning"],"person_names":["and jia tan fang","daokai zhang","dk pharmaceuticaland","dk pharmaceuticaldoes","dk pharmaceuticalis","dk pharmceutical","dongke maidisen","dongke zhao","esq","gengchang wang","guofeng zhang","jia tan fang","jiansheng zhang","jine zhao","jingkun wei","jinhao zhang","jinhuan chang","junlin xu","marc ross","mark dolen","michael segal","peilin xing","post-forward","quanfu yang","ruojing zhao","virz","virz indemnifi","wenyan zhao","william l. macdonald","xiaomin wei","xuejiao wang","xueli yang","yanhong ren","yaolong zhao","zhengyan dai"],"vars":{"Party":{"Ting Zhu":"[[Party 3]]","Virtual Closet, Inc., a Nevada Corporation":"[[Party 2]]","Dong Ke Pharmaceutical, Inc.":"[[Party 1]]"}},"organization_names":["avisa ir services","dk pharmaceu","dk pharmaceutical","dk pharmaceutical disclosure schedules","dk pharmaceutical permit","dk pharmaceutical permits","dk pharmaceutical share records","dk pharmaceutical shareholder","dk pharmaceutical shareholders","dk pharmaceutical shareholders nor dk pharmaceutical","dk pharmaceutical shares","dk pharmaceutical shares exchanged","dk pharmaceuticalafter","dk pharmaceuticalto","dk pharmeutical","exchange dk pharmaceutical shares","ge lin","inc.","ltd.","material dk contract","nsd consulting services, inc.","people’s republic","regulation s","share exchange","shell","sichenzia ross friedman ference llp","tax authority","virz controlling","virz controlling stockholders","virz controlling stockholderss","w.l. macdonald law","w.l. macdonald law corporation","wfoe","yangling dongke maidisen pharmaceutical co.","yangling dongke maidisen pharmaceuticals co.","yangling slovan pharmaceutical co.","yaolong zhao"],"agreement_id":"9b77064b4af43310327ad13fcb0ebbea18e9c8d81c66daeab12e4a6a6ebdc261","terms":["\"**Closing Date**\"","\"**Closing**\"","\"**Corporate Records**\"","\"**DK Pharmaceutical Breach**\"","\"**DK Pharmaceutical Charter Documents**\"","\"**VIRZ Breach**\"","** **","** Within four (4) business days of the Closing Date, VIRZ and DK Pharmaceutical shall have ensuredthat the Transaction Form 8-K has been filed with the SEC.**","**%**","**(Capitalized terms not otherwise defined herein are defined as set forth in the Agreement.)**","**(“Common Stock**”","**/s/ Ge Lin**","**/s/ Jia Tan Fang**","**1,941,818**","**10,015,000**","**10,255,000**","**2,181,818**","**2,999,989**","**26,699,998**","**26,700,000**","**3,300,000**","**30,000,000**","**32,999,989**","**AND THE VIRZ CONTROLLING STOCKHOLDERS]**","**AND**","**Absence of Undisclosed Liabilities**","**Access to Properties and Records**","**Accounting**","**Acquisitions**","**Adverse Changes**","**Agreement to Exchange DK Pharmaceutical Shares for VIRZ Shares**","**Agreements and Covenants**","**Agreements**","**Amendments and Waivers****","**Appointment of New Directors**","**Assurance and Indemnification Letter.**","**Authorization and Validity of Agreements**","**Board Recommendation**","**Books and Financial Records**","**Brokers’ Fees**","**By: /s/ You [[VIRZ Controlling Stockholders]]____________**","**CONDITIONS TO OBLIGATIONS OF DK PHARMACEUTICAL AND THE DK PHARMACEUTICAL SHAREHOLDERS**","**CONDITIONS TO OBLIGATIONS OF VIRZ**","**COVENANTS**","**Capital Stock**","**Capitalization Table**","**Capitalization at the Closing.**","**Capitalization of DK Pharmaceutical; Title to the DK Pharmaceutical Shares**","**Capitalization of VIRZ**","**Certain Changes and Conduct of Business**","**Certificate of Good Standing**","**Certificate**”","**Changes****","**Claims**","**Closing and Actions at Closing**","**Compliance with Laws and Other Instruments**","**Compliance with Laws.**","**Consents and Approvals**","**Consistency in Reporting**","**Consultants**","**Convenience of Forum; Consent to Jurisdiction**","**Corporate Organization**","**Counterparts**","**Current Cap Structure**","**DK Pharmaceutical has at all time been and are in compliance with all Environmental Laws (as defined below) applicable to DK Pharmaceutical.**","**DK Pharmaceutical**","**Debt Cancellation**","**Discharged Liabilities**","**Disclosure Schedules**","**Disclosure**","**Dividends**","**EXCHANGE OF DK PHARMACEUTICAL SHARES FOR VIRZ SHARES**","**EXHIBIT A**","**EXHIBIT B**","**EXHIBIT C**","**Employee Benefit Plans**","**Enforcement of the Agreement**","**Entire Agreement**","**Environmental and Safety Matters**","**Exhibit A**","**Exhibit B**","**Exhibit C**","**Exhibit “A”**","**Exhibit “B”**","**Exhibit “C”**","**Exhibit “D”**","**Exhibit “E”**","**FORM OF OPINION OF COUNSEL TO VIRZ**","**Fees and Expenses**","**Financial Statements; SEC Filings**","**Forward Split**","**Ge Lin**","**Governing Law**","**Governmental Inquiries**","**Guarantees**","**IN WITNESS WHEREOF,**","**Indebtedness**","**Indemnification Obligations in favor of the Executive Officers, Directors, Employees and Controlling Stockholders of VIRZ**","**Indemnification in favor of DK Pharmaceutical and the DK Pharmaceutical Shareholders**","**Indemnification**","**Intellectual Property**","**Interested Party Transactions**","**Investment Representations**","**Jia Tan Fang**","**Licenses**","**Liens**","**List of DK Pharmaceutical Shareholders**","**Litigation**","**Litigation; Orders**","**Loans**","**MISCELLANEOUS PROVISIONS**","**Material Agreements**","**Material Assets****","**Material DK Contracts**","**Methods of Termination**","**NOW, THEREFORE,**","**Negotiations**","**No Broker Fees****","**No Conflict or Violation**","**No Defaults**","**No Disagreements with Accountants and Lawyers**","**No Violation of Orders**","**Notices**","**OCEE**","**Opinions of Counsel, Etc**","**Ordinary Course of Business**","**Other Closing Documents**","**Ownership of Shares**","**POST-CLOSING AGREEMENTS**","**Permits**”","**Pre-emptive Rights**","**Procedure Upon Termination**","**Public Announcement**","**Publicity**","**REPRESENTATIONS AND WARRANTIES OF DK PHARMACEUTICAL AND THE DK PHARMACEUTICAL SHAREHOLDERS**","**REPRESENTATIONS AND WARRANTIES OF VIRZ AND THE VIRZ CONTROLLING STOCKHOLDERS**","**Representations and Warranties of DK Pharmaceutical and the DK Pharmaceutical Shareholders**","**Representations and Warranties of VIRZ and the VIRZ Controlling Stockholders.**","**SCHEDULE 2.3(C )**","**SHARE EXCHANGE AGREEMENT**","**Schedule 2.1 through 2.18**","**Schedule 2.10(a)**","**Schedule 2.3**","**Schedule 2.7**","**Schedule 3.1 through 3.25**","**Schedule 3.13**","**Schedule 3.14(g)**","**Schedule 3.14(n)**","**Schedule 3.19**","**Schedule 3.21**","**Schedule 3.22(a)**","**Schedule 3.22(b)**","**Schedule 3.23**","**Schedule 3.3(a)**","**Schedule 3.7**","**Schedule 3.9**","**Section**","**Severability**","**Shares**”","**Shell**","**Stock Option Plans; Employee Benefits**","**Subsidiaries and Equity Investments**","**Successors and Assigns**","**Survival of Provisions**","**Survival**","**TERMINATION AND ABANDONMENT**","**THE DK PHARMACEUTICAL SHAREHOLDERS:**","**THE SHAREHOLDERS OF [[DK Pharmaceutical]],**","**Tax Returns, Payments and Elections**","**Title to and Condition of Properties**","**Titles and Headings**","**Total**","**Transaction Form 8-K**","**VIRTUAL CLOSET, INC.**","**VIRZ CONTROLLING STOCKHOLDERS**","**WHEREAS**","**WHEREAS,**","**YOU [[VIRZ Controlling Stockholders]], GE LIN, AND JIA TAN FANG**","**[SIGNATURE PAGE FOR VIRTUAL CLOSET, INC.**","**[THE CONTROLLING STOCKHOLDERS OF VIRTUAL CLOSET, INC.]**","**_/s/ You [[VIRZ Controlling Stockholders]]______________**","**by and among**","**dated as of [[Date 1: Date]]**","**further provided, however**","**however**","**provided**","**provided, how ever**","**“DK Pharmaceutical Disclosure Schedules**”","**“DK Pharmaceutical Shares”**","**“Material Adverse Effect”**","**“Subsidiary”**","**“U.S. GAAP”**","**“VIRZ Charter Documents**”","**“VIRZ”**","“**Action**”","“**Agreement**”","“**Approvals**”","“**By-laws**”","“**Cap Table**”","“**Code**”","“**Company**”","“**DK Indemnified Person**”","“**DK Pharmaceutical Share Records”","“**DK Pharmaceutical Share Records”) are true, complete and accurate records of the ownership of the shares of such capital stock as of t he date thereof and contain all issuances and transfers of such shares since the time of organization of DK Pharmaceutical.**","“**DK Pharmaceutical Shareholders**”","“**DK Pharmaceutical**","“**DK Pharmaceutical**”","“**DK Subsidiaries**”","“**Damages**”","“**Directed Selling Effort**”","“**Dongke Maidisen**”","“**Exchange Act**”","“**Financial Statements**”","“**Liens**”","“**Material DK**","“**Permitted Liens**”","“**Public Reports**”","“**SEC**”","“**Sarbanes/Oxley Act**”","“**Securities Act**”","“**Share Exchange**”","“**Survival Period**”","“**Tax Authority**”","“**Tax Returns**”","“**Tax**”","“**Transaction Documents**”","“**VIRZ Disclosure Schedules**”","“**VIRZ Indemnifi ed Party**”","“**VIRZ**","“**VIRZ** **Shares**”","“**WFOE**”","“Common Stock**”","“DK Pharmaceutical”","“Environmental Laws”","“Officer’s Certificate”","“Resolutions”","“”) as attached hereto as **Exhibit “A”**, (iii) Certificate of Good Standing of the Secretary of the State of Nevada, as attached hereto as **Exhibit “B”** for the Company (the “ ;**Certificate**”"]}}